Diabetes
From the Journals
‘Key cause’ of type 2 diabetes identified
“This suggests a potential way in which the decline in beta-cell function in T2D might be slowed or prevented.”
Conference Coverage
Statins boost glycemia slightly, but CVD benefits prevail
Meta-analysis of 23 trials confirmed statins raise glycemia and can trigger diabetes, but the effect pales compared with their CVD prevention.
From the Journals
Has the time come for glucose monitors for people without diabetes?
The increasing popularity of continuous glucose monitoring devices in prediabetes and for ‘wellness’ prompts discussion about appropriate use and...
Conference Coverage
New dual-agonist weight-loss injection impressive, but early days
The “bottom line” is that this potential new antiobesity/diabetes drug is “very promising, but [it is] still a little early to say where it...
Conference Coverage
Tirzepatide lowers weight across all groups with obesity
The antiobesity medication semaglutide “took things up one big notch, and now tirzepatide is up a little notch above that,” one expert said.
Conference Coverage
If a saphenous graft is available, treat limb threatening ischemia surgically
Surgery beats endovascular treatment for limb threatening ischemia when saphenous grafts are an option, according to the BEST-CLI trial.
Conference Coverage
Triglyceride-lowering fails to show CV benefit in large fibrate trial
In the phase 3 PROMINENT trial, pemafibrate improved multiple lipid fractions in patients with type 2 diabetes, without any impact on...
From the Journals
Exercise later in the day for better blood glucose control?
“At this stage, I believe it is most important to be physically active in general. So ... if the morning is the only time of the day to go for a...
Conference Coverage
ObesityWeek 2022: What’s stopping effective treatment of obesity?
In the biggest international conference on obesity, delegates will discuss obesity in children and barriers to use of newer anti-obesity drugs,...
From the Journals
Finerenone: ‘Striking’ cut in pneumonia, COVID-19 risks
Secondary analyses of the finerenone pivotal trials showed that the agent was linked with less infective pneumonia and blunted COVID-19 severity...
From the Journals
Goodbye ‘diabetes insipidus’, hello ‘AVP-D’ and ‘AVP-R’
Confusion with the term ‘diabetes mellitus’ ... has spurred proposed name change by an international panel representing major endocrinology...